ARTORG Center spin-off PeriVision awarded EUR 1.5 million

Bernese start-up PeriVision topped the EIT Wild Card 2021 challenge, winning EUR 1.5 million to finalize its first product and prepare its EU and US market launches.

Currently, 80 million people worldwide suffer from glaucoma, a chronic eye disease that leads to blindness. But the increasing number of those affected and limits to specialized eye care infrastructure cause a significant percentage of these people not to be diagnosed or not get timely doctors’ appointments to slow down disease progression.

PeriVision, a medtech spin-off from the ARTORG Center (AI in Medical Imaging lab) in Bern, wants to ease the burden on the healthcare system and allow everyone easy access to glaucoma care through an innovative portable, fast and easy-to-use Virtual Reality headset supported by visual field testing software to measure glaucoma progression.

The start-up’s patented machine learning algorithm cuts down examination times to have more reliable results.

The annual Wild Card 10-week program builds and supports new ventures tackling some of European healthcare’s greatest challenges, offering coaching and mentorship to the founders-to-be and invests up to EUR 1.5 million in the two most promising ventures.

For the 2021 challenge, the PeriVision team convinced the jury with their “Eye & Vision Care” solution. Besides the investment, Perivision received access to dedicated mentors, the EIT Health network and further acceleration and funding programs.

“We will use this initial money to finalize our product, get the CE and FDA approvals for our medical device and in the meantime prepare our product launch for Europe and US “, said Serife Seda Kucur, co-founder and CTO of PeriVision.